71 related articles for article (PubMed ID: 1210146)
1. [Humoral antitumor cytotoxins in patients with melanoma of the skin].
Korosteleva TA; Veresova OV; Khachaturian LM
Vopr Onkol; 1975; 21(5):61-3. PubMed ID: 1210146
[TBL] [Abstract][Full Text] [Related]
2. [In vitro humeral serum cytotoxic reactions in melanoma].
Korosteleva TA; Veresova OV; Khachaturyan LM
Vopr Onkol; 1979; 25(9):12-4. PubMed ID: 483712
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunological significance of human melanoma cytotoxic antibody.
Bodurtha AJ; Chee DO; Laucius JF; Mastrangelo MJ; Prehn RT
Cancer Res; 1975 Jan; 35(1):189-93. PubMed ID: 1109788
[TBL] [Abstract][Full Text] [Related]
4. [Specific antitumor cytotoxicity of blood platelets from the peripheral blood of patients with lung cancer].
Bykovskaia SN; Blokhina NG; Speranskiĭ DL; Kuprianova TA
Biull Eksp Biol Med; 1988 Jun; 105(6):708-9. PubMed ID: 3390590
[TBL] [Abstract][Full Text] [Related]
5. Antimelanoma immunity in vitiligo and melanoma patients.
Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of the level of humoral cytotoxins and delayed hypersensitivity skin reactions with survival of patients with melanoma of the skin].
Korosteleva TA; Vagner RI; Veresova OV; Potapenkova LS
Vopr Onkol; 1983; 29(4):38-40. PubMed ID: 6858049
[TBL] [Abstract][Full Text] [Related]
7. "Hidden" cytotoxic antibodies that react with allogeneic cultured fetal and tumor cells contained in soluble immune complexes from normal human sera.
Morgan AC; Rossen RD; McCormick KJ; Stehlin JS; Giovanella BC
Cancer Res; 1982 Mar; 42(3):881-7. PubMed ID: 7059986
[TBL] [Abstract][Full Text] [Related]
8. [Cytotoxicity of the lymphocytes of melanoma patients against autologous tumor cells and its in vitro enhancement].
Bykovskaia SN; Iobadze MS; Kupriianova TA; Demidov LV
Biull Eksp Biol Med; 1987 Jan; 103(1):86-9. PubMed ID: 2948576
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of lymphocytes from healthy subjects and from melanoma patients against cultured melanoma cells.
Pavie-Fischer J; Kourilsky FM; Picard F; Banzet P; Puissant A
Clin Exp Immunol; 1975 Sep; 21(3):430-41. PubMed ID: 1204255
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of leukocyte-dependent antibody activity in melanoma patients.
Hersey P; Edwards A; Murray E; McCarthy WH; Milton GW
J Natl Cancer Inst; 1983 Jul; 71(1):45-53. PubMed ID: 6575208
[TBL] [Abstract][Full Text] [Related]
11. [Immunologic response in patients with melanoma of the skin].
Mutsenietse AIa; Volrat AA; Popena BA; Bumbieris IaV; Shapovalova EA
Vopr Onkol; 1983; 29(4):34-8. PubMed ID: 6858048
[TBL] [Abstract][Full Text] [Related]
12. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients.
Rossen RD; Crane MM; Morgan AC; Giannini EH; Giovanella BC; Stehlin JS; Twomey JJ; Hersh EM
Cancer Res; 1983 Jan; 43(1):422-9. PubMed ID: 6600161
[TBL] [Abstract][Full Text] [Related]
13. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor immunoreactivity in patients with malignant melanoma.
Nairn RC; Nind AP; Guli EP; Davies DJ; Little JH; Davis NC; Whitehead RH
Med J Aust; 1972 Feb; 1(9):397-403. PubMed ID: 4554232
[No Abstract] [Full Text] [Related]
15. Infiltrating lymphocytes in benign and malignant naevomelanocytic lesions.
Flageul B; Bachelez H; Boumsell L; Degos L; Bensussan A
Nouv Rev Fr Hematol (1978); 1990; 32(1):9-11. PubMed ID: 2349086
[TBL] [Abstract][Full Text] [Related]
16. Growth and spontaneous regression of swine melanoma: relationship of in vitro leukocyte reactivity.
Berkelhammer J; Ensign BM; Hook RR; Hecker CJ; Smith GD; Oxenhandler RW
J Natl Cancer Inst; 1982 Mar; 68(3):461-8. PubMed ID: 6950174
[TBL] [Abstract][Full Text] [Related]
17. [Cytotoxic immunity indices of melanoma B16 growth in mice].
Korosteleva TA; Veresova OV
Vopr Onkol; 1980; 26(1):67-70. PubMed ID: 7355591
[TBL] [Abstract][Full Text] [Related]
18. Estimation of macrophage IL-10 and NO secretion in the cytotoxicity against transplantable melanomas in relation to the progression of these tumours.
Kozłowska K; Cichorek M; Zarzeczna M
Folia Morphol (Warsz); 2002; 61(3):127-31. PubMed ID: 12416926
[TBL] [Abstract][Full Text] [Related]
19. Use of the antibody-dependent cellular cytotoxicity test to detect antibodies in sera of breast cancer patients.
Plain MJ; Whitehead RH; Jose DG
J Natl Cancer Inst; 1981 Apr; 66(4):619-24. PubMed ID: 7014964
[TBL] [Abstract][Full Text] [Related]
20. Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials.
Zaritskaya L; Shafer-Weaver KA; Gregory MK; Strobl SL; Baseler M; Malyguine A
J Immunother; 2009; 32(2):186-94. PubMed ID: 19238018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
